Literature DB >> 17517623

Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies.

Wenjie Luo1, Fei Dou, Anna Rodina, Sophorn Chip, Joungnam Kim, Qi Zhao, Kamalika Moulick, Julia Aguirre, Nian Wu, Paul Greengard, Gabriela Chiosis.   

Abstract

Neurodegeneration, a result of multiple dysregulatory events, is a lengthy multistep process manifested by accrual of mutant variants and abnormal expression, posttranslational modification, and processing of certain proteins. Accumulation of these dysregulated processes requires a mechanism that maintains their functional stability and allows the evolution of the neurodegenerative phenotype. In malignant cells, the capacity to buffer transformation has been attributed to heat-shock protein 90 (Hsp90). Although normal proteins seem to require limited assistance from the chaperone, their aberrant counterparts seem to be highly dependent on Hsp90. Whereas enhanced Hsp90 affinity for mutated or functionally deregulated client proteins has been observed for several oncoproteins, it is unknown whether Hsp90 plays a similar role for neuronal proteins and thus maintains and facilitates the transformed phenotype in neurodegenerative diseases. Tauopathies are neurodegenerative diseases characterized by aberrant phosphorylation and/or expression of Tau protein, leading to a time-dependent accumulation of Tau aggregates and subsequent neuronal death. Here, we show that the stability of p35, a neuronal protein that activates cyclin-dependent protein kinase 5 through complex formation leading to aberrant Tau phosphorylation, and that of mutant but not WT Tau protein is maintained in tauopathies by Hsp90. Inhibition of Hsp90 in cellular and mouse models of tauopathies leads to a reduction of the pathogenic activity of these proteins and results in elimination of aggregated Tau. The results identify important roles played by Hsp90 in maintaining and facilitating the degenerative phenotype in these diseases and provide a common principle governing cancer and neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17517623      PMCID: PMC1890525          DOI: 10.1073/pnas.0701055104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Polypeptide release by Hsp90 involves ATP hydrolysis and is enhanced by the co-chaperone p23.

Authors:  J C Young; F U Hartl
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

Review 2.  Neurodegenerative tauopathies.

Authors:  V M Lee; M Goedert; J Q Trojanowski
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

3.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein.

Authors:  J Lewis; E McGowan; J Rockwood; H Melrose; P Nacharaju; M Van Slegtenhorst; K Gwinn-Hardy; M Paul Murphy; M Baker; X Yu; K Duff; J Hardy; A Corral; W L Lin; S H Yen; D W Dickson; P Davies; M Hutton
Journal:  Nat Genet       Date:  2000-08       Impact factor: 38.330

4.  A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis.

Authors:  S G Greenberg; P Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

5.  Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease.

Authors:  A Sittler; R Lurz; G Lueder; J Priller; H Lehrach; M K Hayer-Hartl; F U Hartl; E E Wanker
Journal:  Hum Mol Genet       Date:  2001-06-01       Impact factor: 6.150

6.  Fetal-type phosphorylation of the tau in paired helical filaments.

Authors:  K Kanemaru; K Takio; R Miura; K Titani; Y Ihara
Journal:  J Neurochem       Date:  1992-05       Impact factor: 5.372

7.  p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5.

Authors:  L H Tsai; I Delalle; V S Caviness; T Chae; E Harlow
Journal:  Nature       Date:  1994-09-29       Impact factor: 49.962

8.  Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.

Authors:  K Baumann; E M Mandelkow; J Biernat; H Piwnica-Worms; E Mandelkow
Journal:  FEBS Lett       Date:  1993-12-28       Impact factor: 4.124

9.  Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline-dependent protein kinases.

Authors:  T J Singh; T Zaidi; I Grundke-Iqbal; K Iqbal
Journal:  FEBS Lett       Date:  1995-01-16       Impact factor: 4.124

Review 10.  Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer.

Authors:  Edward McDonald; Paul Workman; Keith Jones
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

View more
  132 in total

Review 1.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 2.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Hsp70 ATPase Modulators as Therapeutics for Alzheimer's and other Neurodegenerative Diseases.

Authors:  Umesh K Jinwal; John Koren; John C O'Leary; Jeffrey R Jones; Jose F Abisambra; Chad A Dickey
Journal:  Mol Cell Pharmacol       Date:  2010-01-01

4.  Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models.

Authors:  Janet van Eersel; Yazi D Ke; Xin Liu; Fabien Delerue; Jillian J Kril; Jürgen Götz; Lars M Ittner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

5.  Accelerated neurodegeneration through chaperone-mediated oligomerization of tau.

Authors:  Laura J Blair; Bryce A Nordhues; Shannon E Hill; K Matthew Scaglione; John C O'Leary; Sarah N Fontaine; Leonid Breydo; Bo Zhang; Pengfei Li; Li Wang; Carl Cotman; Henry L Paulson; Martin Muschol; Vladimir N Uversky; Torsten Klengel; Elisabeth B Binder; Rakez Kayed; Todd E Golde; Nicole Berchtold; Chad A Dickey
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

6.  Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism.

Authors:  Amirthaa Suntharalingam; Jose F Abisambra; John C O'Leary; John Koren; Bo Zhang; Myung Kuk Joe; Laura J Blair; Shannon E Hill; Umesh K Jinwal; Matthew Cockman; Adam S Duerfeldt; Stanislav Tomarev; Brian S J Blagg; Raquel L Lieberman; Chad A Dickey
Journal:  J Biol Chem       Date:  2012-10-03       Impact factor: 5.157

Review 7.  Challenging Proteostasis: Role of the Chaperone Network to Control Aggregation-Prone Proteins in Human Disease.

Authors:  Tessa Sinnige; Anan Yu; Richard I Morimoto
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

8.  Hsp90-Tau complex reveals molecular basis for specificity in chaperone action.

Authors:  G Elif Karagöz; Afonso M S Duarte; Elias Akoury; Hans Ippel; Jacek Biernat; Tania Morán Luengo; Martina Radli; Tatiana Didenko; Bryce A Nordhues; Dmitry B Veprintsev; Chad A Dickey; Eckhard Mandelkow; Markus Zweckstetter; Rolf Boelens; Tobias Madl; Stefan G D Rüdiger
Journal:  Cell       Date:  2014-02-27       Impact factor: 41.582

Review 9.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

Review 10.  Association of heat-shock proteins in various neurodegenerative disorders: is it a master key to open the therapeutic door?

Authors:  Subhankar Paul; Sailendra Mahanta
Journal:  Mol Cell Biochem       Date:  2013-10-05       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.